Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAnthem denosumab coverage update: Coding & PA | Op…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0027

    Denosumab Agents (Prolia, Xgeva, and Biosimilars) — Clinical Coverage Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0027 alerts

    Get alerted when Policy CC-0027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria, step therapy, quantity limits, and coding for denosumab products (Prolia, Xgeva, and listed biosimilars) for osteoporosis and metabolic bone disease; applies to Anthem medical benefit reviews and prior authorization determinations.

    Policy Summary
    PayerAnthem
    PolicyDenosumab Agents (Prolia, Xgeva, and Biosimilars) — Clinical Coverage Criteria
    Policy CodePolicy CC-0027
    Change TypeMaterial coding, product and step therapy updates
    Effective DateMar 26, 2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionSubmit prior authorization with the specific denosumab product name and the matching HCPCS/J/Q code and required clinical documentation (DXA T-score or fragility fracture history) to support approval.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added Boncresa (Prolia biosimilar) and Oziltus (Xgeva biosimilar) to respective clinical criteria and quantity limits; updated step therapy tables and coding.

    Added Osvyrti (Prolia biosimilar) and Jubereq (Xgeva biosimilar) to clinical criteria and quantity limits; updated step therapy and coding.

    Multiple prior coding updates: separation of Prolia and Xgeva biosimilar coding and multiple HCPCS/Q-code assignments added/removed across review dates.

    2primary coverage groups (Osteoporosis; Metabolic bone disease)
    60 mg/6 moProlia/biosimilar osteoporosis dosing limit
    120 mg/28 dXgeva/biosimilar oncology dosing limit
    >=12denosumab biosimilar product names referenced
    2018-2026comprehensive revision log

    Coverage Criteria for Denosumab Agents

    Initial therapy — Denosumab agents for Osteoporosis

    Covered when ANY of the following groups of conditions are met (document preserves OR-grouping):

    Group A: DXA diagnosis with fracture or risk factors: Individual is a male or postmenopausal female with a diagnosis of osteoporosis by BMD T-score ≤ -2.5 at spine, femoral neck, total hip or distal 1/3 radius; AND (has ≥1 osteoporotic (minimal trauma) fracture OR has ≥2 risk factors for osteoporotic fracture OR has failed, is intolerant to, or has a contraindication to other available osteoporosis therapies)
    Group B: Fragility fracture diagnosis: Individual is a male or postmenopausal female with a diagnosis of osteoporosis based on history of at least one low-trauma (fragility) fracture
    Group C: Glucocorticoid-induced osteoporosis: Individual has glucocorticoid-induced osteoporosis (BMD T-score ≤ -2.5 or clinical diagnosis by history of low-trauma fracture) AND is initiating or continuing systemic glucocorticoids at ≥7.5 mg prednisone (or equivalent) daily expected for ≥6 months; AND (has ≥1 osteoporotic fracture OR ≥2 risk factors OR failed/intolerant/contraindicated to other therapies)
    Group D: Cancer therapy–associated bone loss: Individual is a postmenopausal (natural or induced) female receiving adjuvant aromatase inhibitor therapy for breast cancer OR a male receiving androgen deprivation therapy for non-metastatic prostate cancer; AND (has ≥1 osteoporotic fracture OR ≥1 additional risk factor for osteoporotic fracture)

    Denosumab agents for Metabolic Bone Disease (Xgeva-type)

    Covered when ALL of the following are met:

    Adult use for SRE prevention: Individual is ≥18 years of age AND using for prevention of skeletal-related events in one of: multiple myeloma; bone metastases from a solid tumor other than prostate cancer; OR bone metastases from castration-resistant/recurrent prostate cancer.
    Hypercalcemia of malignancy: Individual is ≥18 years of age AND using for treatment of hypercalcemia of malignancy defined as albumin-corrected serum calcium > 12.5 mg/dL (3.1 mmol/L) AND is refractory to intravenous bisphosphonate therapy within the last 30 days.
    Giant cell tumor of bone (GCTB): Using for localized or metastatic unresectable giant cell tumor of bone where surgery is likely to result in severe morbidity AND (individual is ≥18 years OR is a skeletally mature adolescent [closed long-bone growth plate]).

    Continuation therapy criteria

    Covered when ALL of following are met:

    Response and monitoring: There is clinically significant response to therapy (for example: no new fractures, reduction or no worsening of vertebral fractures, and no clinically significant adverse reaction); AND if the individual has been on therapy ≥ 24 months, a repeat BMD demonstrates stable or increased BMD.

    Product-specific coverage

    Covered when product-specific clinical criteria and coding match the indication and step therapy/formulary requirements

    Product + Indication + Correct Coding: Request must identify the denosumab product (Prolia, Xgeva, or specified biosimilar), document the clinical indication supported by an appropriate ICD-10 code (e.g., M80/M81 for osteoporosis for Prolia-type products; malignant neoplasm/bone metastasis codes for Xgeva-type products), AND submit the corresponding HCPCS/J/Q code listed in the policy.

    Follow product-specific HCPCS/Q-code assignments and effective dates as specified in the document history and benefit tables.

    Formulary-dependent criteria

    Formulary and benefit-line differentiated coverage

    Formulary status: Coverage path depends on Commercial versus Medicare benefit and the date of service: products are designated preferred or non-preferred on specified effective dates; non-preferred products may require step therapy or additional justification.

    See benefit tables for specific preferred/non-preferred product lists and effective dates (Commercial and Medicare sections).

    Denosumab products are not approved for use in combination with another denosumab agent. The policy explicitly states that Xgeva-type products (and listed biosimilars) are not approved “In combination with another denosumab agent” and that Prolia-type products “may not be approved” for uses outside the specified clinical criteria, including combination use. Requests that involve co-administration of two denosumab products should be denied per the coverage exclusions.

    Requests that do not meet the clinical criteria for the relevant denosumab product group (Prolia-type for osteoporosis or Xgeva-type for metabolic bone disease) are not eligible for approval; providers must document the specific indication and meet the product-specific clinical requirements and quantity limits to support authorization.

    An update effective 8/15/2025 added a clear criterion that denosumab "may not be used in combination" with other denosumab agents. This annual review entry reinforces that step therapy tables were adjusted at that time to align biosimilar sequencing and that combination use is explicitly prohibited in the policy language.

    Providers requesting denosumab should ensure the request does not involve simultaneous use of another denosumab product; failure to follow this restriction is a basis for denial under the revised criteria.

    Approval of denosumab is contingent on meeting the clinical criteria specific to the product group. Continuation criteria for Prolia and its biosimilars require demonstration of clinically significant response (for example, no new fractures or no worsening vertebral fractures) and, when on therapy ≥24 months, stable or increased BMD on repeat DXA. For Xgeva-type products, approval requires meeting the metabolic bone disease criteria (e.g., skeletal-related event prevention in adults, hypercalcemia of malignancy with albumin-corrected calcium > 12.5 mg/dL and refractory to IV bisphosphonate, or unresectable giant cell tumor of bone in appropriate patients).

    If the submitted request does not document the required clinical findings, diagnostic codes, or meets the defined thresholds (including quantity limits and prior therapy requirements), it is not eligible for approval.

    The policy restricts combination use of denosumab with other agents and notes that such combinations may be considered not medically necessary. The Xgeva grouping specifically lists combination use with other denosumab products as a non‑approvable condition, and the document history records the addition of this restriction in the 8/15/2025 annual review.

    Requests suggesting or documenting combination therapy with another denosumab product should be treated as medically unnecessary unless documentation shows adherence to an approved, single-product clinical pathway described in this policy.

    Codes, Diagnosis, and Quantity Limits

    Prolia and biosimilar HCPCS/J-codesHCPCS
    C9399Unclassified drugs or biologicals [when specified as Enoby (denosumab-qbde), or Osvyrti (denosumabdesu)]
    J0897Injection, denosumab, 1 mg [Prolia]
    Q5157Injection, denosumab-bmwo (Stoboclo), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Conexxence), biosimilar, 1 mg
    Q5159Injection, denosumab-dssb (Ospomyv), biosimilar, 1 mg
    Q5161Injection, denosumab-kyqq (Bosaya), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (Bildyos), biosimilar, 1 mg
    ICD-10 Diagnosis codesICD-10
    M80.00XA-M80.88XSOsteoporosis with current pathological fracture (range listed)
    M81.0-M81.8Osteoporosis without current pathological fracture
    M85.80-M85.9Other specified disorders of bone density and structure
    N95.1Menopausal and female climacteric states
    C61Malignant neoplasm of prostate
    Z79.51-Z79.52Long term (current) use of steroids
    Denosumab (Prolia) codes and biosimilarsHCPCSCovered
    C9399Unclassified drugs or biologicals [when specified as Enoby (denosumab-qbde), or Osvyrti (denosumabdesu)]
    J0897Injection, denosumab, 1 mg [Prolia]
    Q5157Injection, denosumab-bmwo (Stoboclo), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Conexxence), biosimilar, 1 mg
    Q5159Injection, denosumab-dssb (Ospomyv), biosimilar, 1 mg
    Q5161Injection, denosumab-kyqq (Bosaya), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (Bildyos), biosimilar, 1 mg
    (J0897 duplicate entry noting unclassified biologics usage)Unclassified biologics [when specified as Boncresa (denosumab-mobz), Enoby (denosumab-qbde), or Osvyrti (denosumab-desu)]
    Denosumab (Xgeva) codes and biosimilarsHCPCSCovered
    C9399Unclassified drugs or biologicals [when specified as Jubereq (denosumab-desu), Oziltus (denosumab-mobz) or Xtrenbo (denosumab-qbde)]
    J3590Unclassified biologics [when specified as Jubereq (denosumab-desu), or Xtrenbo (denosumab-qbde)]
    Q5136Injection, denosumab-bmwo (Osenvelt), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Bomyntra), biosimilar, 1 mg
    Q5159Injection, denosumab-dssb (Xbryk), biosimilar, 1 mg
    Q5162Injection, denosumab-kyqq (Aukelso), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (Bilprevda), biosimilar, 1 mg
    Relevant ICD-10 diagnosis codes referencedICD-10
    C50.011-C50.929Malignant neoplasm of breast (examples listed across earlier revisions)
    C61Malignant neoplasm of prostate
    M80.00XA-M80.88XSPathological fracture codes
    M81.0-M81.8Osteoporosis codes
    M85.80-M85.9Other specified disorders of bone density and structure [osteopenia]
    C79.51Secondary malignant neoplasm of bone
    C90.00-C90.32Multiple myeloma and malignant plasma cell neoplasms
    inv-15: Hypercalcemia of malignancy serum calcium — threshold value
    Hypercalcemia of malignancy threshold> 12.5 mg/dL (3.1 mmol/L) albumin-corrected serum calcium
    Refractory requirementMust be refractory to IV bisphosphonate within the last 30 days
    Age requirementIndividual is 18 years of age or older for this indication
    inv-16: Quantity limits — 60 mg every 6 months (osteoporosis agents); 120 mg per 28 days (metabolic bone disease agents)
    Osteoporosis agents (Prolia-type)60 mg (1 prefilled syringe) every 6 months

    Provider Requirements, Prior Authorization, and Denial Triggers

    Prior Authorization

    Prior authorization required and contingent on meeting clinical criteria

    Prior authorization is required for all denosumab agents; approval is contingent on meeting the product-specific clinical criteria for osteoporosis (Prolia-type) or metabolic bone disease (Xgeva-type) and adherence to the quantity limits (60 mg every 6 months for Prolia-type; 120 mg per 28 days for Xgeva-type).

    • Initial and continuation requests are reviewed under the clinical criteria sections for Prolia- or Xgeva-type agents.
    • Quantity limits must match the product type (Prolia-type 60 mg/6 months; Xgeva-type 120 mg/28 days).
    Prior Authorization

    Prior authorization must include product-specific HCPCS/J/Q code

    Submit the specific denosumab product name with the matching HCPCS/J/Q code when requesting prior authorization; formulary/preferred status by benefit line and date of service affects approval requirements.

    • Examples of product-level codes include J0897, C9399, and Q-series codes (see coding tables).

    Background and Drug Information

    Denosumab is a subcutaneous, fully human monoclonal antibody that targets receptor activator of nuclear factor kappa‑B ligand (RANKL). It is FDA‑approved for multiple indications across two primary clinical groups: osteoporosis (Prolia and biosimilars) and metabolic bone disease/oncology indications (Xgeva and biosimilars).

    Approved uses in the policy include treatment of osteoporosis in men and postmenopausal women (guided by DXA T‑score criteria and fracture risk), prevention of skeletal‑related events from bone metastases or multiple myeloma, treatment of hypercalcemia of malignancy (albumin‑corrected serum calcium > 12.5 mg/dL and refractory to IV bisphosphonate), and treatment of unresectable or morbid giant cell tumor of bone in appropriate patients.

    Definitions and Clinical Thresholds

    inv-27: Osteoporosis — Diagnostic criteria (BMD T-score ≤ -2.5 or fragility fracture)
    BMD diagnostic thresholdDiagnosis by DXA with a T-score ≤ -2.5 at spine, femoral neck, total hip or distal 1/3 radius
    Clinical diagnosis by fractureHistory of a fragility (low-trauma) fracture qualifies as osteoporosis diagnosis
    Monitoring guidanceObtain baseline axial DXA (spine and hip; 1/3 radius if indicated) and repeat DXA every 1–2 years after treatment initiation until stable
    inv-28: High fracture risk — Definition includes prior fracture, risk factors, or failure/intolerance to other therapies
    Definition of high fracture riskHistory of osteoporotic fracture or multiple risk factors (eg, advanced age, low BMD, low body weight, glucocorticoid use, smoking, excessive alcohol, secondary osteoporosis)
    Failure/intolerance criterion
    Policy Summary
    PayerAnthem
    PolicyDenosumab Agents (Prolia, Xgeva, and Biosimilars) — Clinical Coverage Criteria
    Policy CodePolicy CC-0027
    Change TypeMaterial coding, product and step therapy updates
    Effective DateMar 26, 2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionSubmit prior authorization with the specific denosumab product name and the matching HCPCS/J/Q code and required clinical documentation (DXA T-score or fragility fracture history) to support approval.
    SourceLink
    On This Page
    Coverage Criteria for Denosumab AgentsCodes, Diagnosis, and Quantity LimitsProvider Requirements, Prior Authorization, and Denial TriggersBackground and Drug InformationDefinitions and Clinical Thresholds
    Metabolic bone disease agents (Xgeva-type)
    120 mg (1 vial) per 28 days
    Giant cell tumor or hypercalcemia overrideRequests for increased quantities may be approved during first month for up to two additional 120 mg doses for GCTB or hypercalcemia of malignancy
    inv-17: Diagnosis code ranges — Specific ICD-10 code ranges required to support indication
    Malignant neoplasm code range examplesC00.0-C76.8; plus secondary bone metastasis C79.51 and multiple myeloma C90.00-C90.32
    Osteoporosis code rangesM80.00XA-M80.88XS (osteoporosis with current pathologic fracture); M81.0-M81.8 (osteoporosis without current pathologic fracture)
    Other bone disorder codesM85.80-M85.9 (other disorders of bone density/structure); D48.0 (neoplasm of uncertain behavior of bone - GCTB)
  1. Formulary lists (Commercial and Medicare) and document history show product-specific coding and effective dates that determine PA processing.
  2. Step Therapy

    Step therapy: use preferred denosumab agent or document intolerance

    Plan-level step therapy may require use of a preferred denosumab agent; requests for non-preferred agents require documentation of a trial and an allergy or severe intolerance to an inactive ingredient in the preferred agent.

    • Preferred agent lists are maintained by the plan; providers should reference the plan's preferred-agent list when initiating PA.
    • Non-preferred requests based on convenience (device, concentration, regimen) are not sufficient for approval.
    Step Therapy

    Updated step therapy requirements for biosimilars

    Step therapy tables and sequences have been added/updated to align biosimilar use with standard biosimilar step therapy criteria; follow the updated step therapy sequence when requesting non-preferred biosimilars.

    • Document history notes addition of step therapy tables and alignment with biosimilar step therapy (8/15/2025 and subsequent updates).
    • Providers must follow the updated step therapy sequences in the policy when requesting non-preferred biosimilars.
    Documentation Required

    Required clinical documentation: DXA, fractures, risk factors, prior therapy

    Include clinical documentation that supports the diagnosis and indication: DXA BMD T-score results or history of fragility fracture, relevant risk factors, prior osteoporosis therapy trials, intolerance or contraindications, and repeat BMD when applicable.

    • Osteoporosis defined as BMD T-score ≤ -2.5 in spine, femoral neck, total hip or distal 1/3 radius.
    • For continuation after ≥24 months, provide repeat BMD showing stable or increased BMD and evidence of clinical response (no new fractures).
    Documentation Required

    Product-level coding must be documented (product name + HCPCS/J/Q code)

    Document the exact denosumab product and bill using the corresponding HCPCS/J/Q code listed in the policy (examples include J0897 for Prolia; Q5157–Q5162 and C9399/J3590 where specified for biosimilars).

    • Coding tables list product-to-code mappings and note when C9399 or J3590 may be used with a specified product.
    • Recent document history shows additions/removals and effective dates for Q-codes—use current policy coding assignments for PA and claims.
    Denial Risk

    Denial triggers: combination use or unmet clinical criteria

    Requests will be denied when a denosumab product is used in combination with another denosumab agent or when the submitted clinical information does not meet the policy criteria for the specified indication.

    • Policy explicitly lists 'In combination with another denosumab agent' as a non-approved use for both Prolia- and Xgeva-type sections.
    • Requests lacking the required clinical criteria for the chosen product/indication are not eligible for approval.
    Billing Rule

    Coding-based denial risk: use current HCPCS/Q-code assignments and effective dates

    Claims and authorizations may be denied or impacted if providers submit doses under HCPCS NOC codes that were removed or use product codes inconsistent with the policy's current coding updates and effective dates; ensure coding reflects the latest document history.

    • Document history shows removals from C9399/J3590 effective 3/31/26 and additions of Q5161/Q5162 effective 4/1/26—use the codes effective for the date of service.
    • Multiple prior coding updates and separations of Prolia vs Xgeva biosimilar coding are documented; billing must follow the policy's current assignments.
    Failure or intolerance to other osteoporosis therapies (eg, decline in BMD ≥5% on therapy or fragility fracture while on therapy) supports high-risk designation
    Glucocorticoid exposure considerationUse of glucocorticoids (≥5 mg prednisone daily for ≥3 months) is a listed risk factor increasing fracture risk
    inv-29: Denosumab biosimilar — Definition and relation to reference products (Prolia/Xgeva)
    Definition of denosumab biosimilarFDA‑approved alternative biologic products referencing the denosumab reference products (Prolia/Xgeva) with distinct HCPCS/Q-code assignments
    Relation to reference productsBiosimilars are linked to the reference products Prolia (osteoporosis) and Xgeva (metabolic bone disease) and listed by proprietary and proper names in the policy
    Coding and naming examplesExamples include Boncresa (denosumab-mobz), Bildyos (denosumab-nxxp), Bosaya (denosumab-kyqq), Enoby (denosumab-qbde), among others with specific HCPCS/Q codes assigned in the policy